AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
CervoMed: D. Boral Capital Raises Buy Rating, PT to $31 from $15
ByAinvest
Monday, Aug 18, 2025 7:48 am ET1min read
CervoMed: D. Boral Capital Raises Buy Rating, PT to $31 from $15
D. Boral Capital has significantly raised its price target for CervoMed Inc. (NASDAQ: CRVO) to $31 from $15, while maintaining a Buy rating on the stock. This move follows the company's recent earnings report and positive clinical trial results. The research firm cited a strengthened translational link between drug exposure and clinical benefit demonstrated with the New Capsule formulation, which has improved the probability of clinical success for neflamapimod in dementia with Lewy bodies from 10% to 15% [3].CervoMed reported a net loss of $6.3 million for the second quarter of 2025, an increase from the $2.3 million net loss in the same period in 2024. The company's cash position as of June 30, 2025, was approximately $33.5 million, down from $38.9 million as of December 31, 2024 [1]. Despite the financial setback, CervoMed's RewinD-LB trial showed promising results, with a 54% risk reduction in clinically significant worsening for patients treated with neflamapimod compared to control at Week 32, improving to 64% among patients with minimal evidence of Alzheimer’s disease co-pathology [1].
The company also enrolled the first patients in a Phase 2a trial of neflamapimod in patients recovering from acute stroke and initiated a Phase 2a trial in patients with the nonfluent/agrammatic variant of primary progressive aphasia [1]. These developments have led to increased interest from institutional investors, with several hedge funds making significant purchases over the past quarters [2].
CervoMed plans to meet with the FDA in the fourth quarter of 2025 to align on the design of the planned Phase 3 trial, which is expected to initiate in mid-2026, subject to available funding [1]. The company's strong financial position, with $35.2 million in cash and securities, is expected to support operations into mid-2026 [3].
References:
[1] https://www.tradingview.com/news/tradingview:74e7bd819cdc5:0-cervomed-reports-second-quarter-2025-financial-results-and-provides-corporate-updates/
[2] https://www.marketbeat.com/instant-alerts/cervomed-nasdaqcrvo-price-target-raised-to-1500-2025-08-11/
[3] https://www.investing.com/news/analyst-ratings/cervomed-stock-price-target-raised-to-15-from-10-at-d-boral-capital-93CH-4182690
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet